We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.81B
1-Year Est. Return 192.15%
This Fund
S&P 500
This Quarter Est. Return
+24.45%
1 Year Est. Return
+192.15%
3 Year Est. Return
+320.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.81B
AUM Growth
+$188M
Cap. Flow
+$7.54M
Cap. Flow %
0.42%
Top 10 Hldgs %
72.72%
Holding
43
New
4
Increased
12
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$66.3M
2
LEGN icon
Legend Biotech
LEGN
+$38.4M
3
RLAY icon
Relay Therapeutics
RLAY
+$27.2M
4
CTMX icon
CytomX Therapeutics
CTMX
+$25.5M
5
SMMT icon
Summit Therapeutics
SMMT
+$21.3M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$36.7M
2
APLS
Apellis Pharmaceuticals
APLS
+$33.2M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$28.6M
4
BEAM icon
Beam Therapeutics
BEAM
+$25.4M
5
VERA icon
Vera Therapeutics
VERA
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
1
Celldex Therapeutics
CLDX
$3.12B
$198M 10.95%
5,322,908
-517,659
-9% -$16.7M
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.84B
$176M 9.73%
8,050,959
– –
PCVX icon
3
Vaxcyte
PCVX
$9.1B
$170M 9.39%
2,922,335
– –
COGT icon
4
Cogent Biosciences
COGT
$6.03B
$142M 7.84%
3,667,097
-370,234
-9% -$13M
VERA icon
5
Vera Therapeutics
VERA
$2.59B
$124M 6.85%
2,890,059
-508,165
-15% -$18.9M
VRDN icon
6
Viridian Therapeutics
VRDN
$2.6B
$119M 6.55%
6,453,877
+4,112,225
+176% +$66.3M
TVTX icon
7
Travere Therapeutics
TVTX
$6.15B
$114M 6.28%
2,000,000
+430,982
+27% +$19.1M
BEAM icon
8
Beam Therapeutics
BEAM
$3.06B
$97.5M 5.39%
2,840,792
-841,393
-23% -$25.4M
URGN icon
9
UroGen Pharma
URGN
$2.16B
$89.6M 4.95%
2,434,207
+186,814
+8% +$5.06M
LEGN icon
10
Legend Biotech
LEGN
$4.19B
$86.7M 4.79%
3,001,205
+1,424,910
+90% +$38.4M
CTMX icon
11
CytomX Therapeutics
CTMX
$808M
$81.4M 4.5%
21,703,093
+6,690,000
+45% +$25.5M
RLAY icon
12
Relay Therapeutics
RLAY
$4.17B
$61.7M 3.41%
3,300,000
+1,875,741
+132% +$27.2M
CGEM icon
13
Cullinan Oncology
CGEM
$1.42B
$56.7M 3.13%
3,114,132
– –
MBX
14
MBX Biosciences
MBX
$2.97B
$51.6M 2.85%
934,799
– –
IMCR icon
15
Immunocore
IMCR
$1.86B
$43.7M 2.41%
1,375,000
+490,063
+55% +$14.5M
NRIX icon
16
Nurix Therapeutics
NRIX
$2.71B
$29M 1.6%
1,194,757
– –
STRO icon
17
Sutro Biopharma
STRO
$333M
$29M 1.6%
872,558
– –
BCRX icon
18
BioCryst Pharmaceuticals
BCRX
$2.55B
$25.2M 1.39%
2,522,660
-3,158,135
-56% -$28.6M
PHVS icon
19
Pharvaris
PHVS
$2.47B
$22.9M 1.26%
661,795
+21,400
+3% +$647K
SMMT icon
20
Summit Therapeutics
SMMT
$14B
$17.5M 0.97%
+1,200,000
New +$21.3M
PRLD icon
21
Prelude Therapeutics
PRLD
$436M
$12.9M 0.71%
2,415,087
+822,536
+52% +$3.58M
INSM icon
22
Insmed
INSM
$27.6B
$10.7M 0.59%
+100,000
New +$12.1M
BNR
23
Burning Rock Biotech
BNR
$126M
$10.5M 0.58%
1,238,563
+11,008
+0.9% +$156K
GERN icon
24
Geron
GERN
$1.01B
$8.75M 0.48%
6,836,318
– –
AMRN
25
Amarin Corp
AMRN
$288M
$8.5M 0.47%
532,982
+60,600
+13% +$895K
1
2

Similar funds

AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.81B AUM 52.11% 1-Year Est. Return
LPT
Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return
SFG
Sage Financial Group W. Conshohocken, Pennsylvania $1.81B AUM 22.3% 1-Year Est. Return
GA
Greenspring Advisors Towson, Maryland $1.8B AUM 22.29% 1-Year Est. Return
CCS
Concentric Capital Strategies Stamford, Connecticut $1.8B AUM 51.77% 1-Year Est. Return
PPW
Parcion Private Wealth Bellevue, Washington $1.8B AUM 30.57% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.8B AUM 22.23% 1-Year Est. Return

Kynam Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Kynam Capital Management held 43 positions worth $1.81B, up 12% from $1.62B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Kynam Capital Management's Q2 2026 filing shows 4 new, 12 increased, 7 reduced and 11 closed positions. Its largest new stake was Summit Therapeutics: 1,200,000 shares worth $17.5M. The largest sale was KalVista Pharmaceuticals, an estimated $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

  • Kynam Capital Management's largest Q2 2026 buy was Summit Therapeutics: 1,200,000 shares worth $17.5M.
  • Kynam Capital Management added most to Viridian Therapeutics in Q2 2026, an estimated $66.3M increase.
  • Kynam Capital Management's biggest Q2 2026 reduction was BioCryst Pharmaceuticals, cutting an estimated $28.6M.
  • Kynam Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $36.7M.
  • Kynam Capital Management's ten largest holdings make up 73% of its $1.81B portfolio in Q2 2026.
  • Kynam Capital Management opened 4 new positions and closed 11 in Q2 2026.
  • Kynam Capital Management's portfolio value rose 12% quarter-over-quarter to $1.81B.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.